Neutralization of Human Extrinsic (Tissue-Type) Plasminogen Activator in Human Plasma: No Evidence for a Specific Inhibitor

No abstract is available for this paper.

• Publication year

  1981

• Venue

  Thrombosis and Haemostasis

• Publication date

  1981-10-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1055/s-0038-1653443PMID 6171907
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A group of patients with impaired plasma fibrinolytic system and selective inhibition of tissue activator-induced fibrinolysis.

  2009cited by this paper
• Purification and characterization of the plasminogen activator secreted by human melanoma cells in culture.

  1981cited by this paper
• Purification and characterization of human antiplasmin, the fast-acting plasmin inhibitor in plasma.

  1977cited by this paper
• Inhibitors of Plasminogen Activation in Human Blood

  1976cited by this paper
• The primary inhibitor of plasmin in human plasma.

  1976cited by this paper
• Inhibition of urokinase by complex formation with human alpha1-antitrypsin.

  1976cited by this paper
• Isolation and characterization of alpha2-plasmin inhibitor from human plasma. A novel proteinase inhibitor which inhibits activator-induced clot lysis.

  1976cited by this paper
• Inhibition of urokinase by complex formation with human α1-antitrypsin

  1976cited by this paper
• Identification and some properties of a new fast-reacting plasmin inhibitor in human plasma.

  1976cited by this paper
• The resistance of fibrinogen and soluble fibrin monomer in blood to degradation by a potent plasminogen activator derived from cadaver limbs.

  1975cited by this paper
• STUDIES ON HUMAN PLASMA α2-MACROGLOBULIN-ENZYME INTERACTIONS

  1973cited by this paper
• Human serum plasminogen antiactivator: its distinction from antiplasmin.

  1971cited by this paper
• Plasminogen: Purification from Human Plasma by Affinity Chromatography

  1970cited by this paper
• A Method for the Quantitative Assay of Inhibitor of Plasminogen Activation in Human Serum

  1967cited by this paper
• A method for the quantitative assay of inhibitor of plasminogen activation in human serum.

  1967cited by this paper
• Determination of alpha-2-macroglobulin as trypsin-protein esterase.

  1966cited by this paper
• Determination of α2-macroglobulin as trypsin-protein esterase

  1966cited by this paper
• A method for determining serum inhibitors of plasminogen activation.

  1962cited by this paper
• Efficient Trace-labelling of Proteins with Iodine

  1958cited by this paper

• The fibrinolytic system in disease: From molecular pathways to clinical outcomes.

  2025cites this paper
• Alpha‐2‐macroglobulin in hemostasis and thrombosis: An underestimated old double‐edged sword

  2022cites this paper
• Identificación y caracterización de genes regulados por NOR-1 (Neuron-derived Orphan Receptor-1): implicación en el remodelado vascular y la diferenciación celular

  2016cites this paper
• Pharmacokinetics and Pharmacodynamics of Fibrinolytic Agents

  2015cites this paper
• Trombolisis con el activador tisular del plasminógeno

  2012cites this paper
• plasminogen activator level Initiation and regulation of fibrinolysis in human plasma at the

  2011cites this paper
• The fibrinolytic enzyme system : New markers of potential interest in cardiovascular disease

  2005cites this paper
• Determinationof Tissue PlasminogenActivatorand Its “ Fast ” Inhibitorin Plasma

  2004cites this paper
• Automated latex photometric immunoassay for total plasminogen activator inhibitor-1 in plasma.

  2003cites this paper
• Detection of mutations in the hepatitis B virus polymerase gene.

  2003cites this paper
• Effective lysis of model thrombi by a t-PA mutant (A473S) that is resistant to alpha2-antiplasmin.

  2000cites this paper
• Determination, pharmacokinetics and protein binding of a novel tissue-type plasminogen activator, pamiteplase in human plasma

  2000cites this paper
• Effective lysis of model thrombi by a t‐PA mutant (A473S) that is resistant to α2‐antiplasmin

  2000cites this paper
• Interaction of human tissue plasminogen activator (t-PA) with pregnancy zone protein: a comparative study with t-PA-alpha2-macroglobulin interaction.

  1998cites this paper
• Tissue plasminogen activator (tPA) antigen in plasma: correlation with different tPA/inhibitor complexes.

  1998cites this paper
• Roles of α2-Macroglobulin and its Receptor in the Regulation of the Plasminogen-Plasmin System

  1997cites this paper
• Studies on the Metabolic Fate of Modified Recombinant Tissue-Type Plasminogen Activator (E6010) (1): Blood or Plasma Concentration, Distribution, Metabolism and Excretion in Rats after a Single Intravenous Administration of 125I-E-6010 in Comparison with 125I-Recombinant Tissue-Type Plasminogen Acti

  1996cites this paper
• Substitution of Serine or Threonine at Position 473 of Tissue-type Plasminogen Activator Increases its Stability in Plasma

  1996cites this paper
• Proteinases from the fibrinolytic and coagulation systems: Analyses of binding to pregnancy zone protein, a pregnancy-associated plasma proteinase inhibitor

  1995cites this paper
• Comparison of Recombinant Single- and Two-chain Tissue Plasminogen Activator in Clot Binding, Fibrinolysis, and Fibrinogenolysis in Vitro

  1994cites this paper
• In Vitro Stability of a Tissue-Type Plasminogen Activator Mutant, BM 06.022, in Human Plasma

  1994cites this paper
• Production and Characterization of a Novel Tissue‐Type Plasminogen Activator Derivative in Escherichia coli

  1994cites this paper
• Complex formation between protein c inhibitor and tissue plasminogen activator during thrombolytic therapy: Evidence of activation of protein C pathway

  1993cites this paper
• Alpha-2-macroglobulin functions as an inhibitor of fibrinolytic, clotting, and neutrophilic proteinases in sepsis: studies using a baboon model

  1993cites this paper
• Fibrinolysis in patients with acute ischaemic heart disease. With particular reference to systemic effects of tissue-type plasminogen activator treatment on fibrinolysis, coagulation and complement pathways.

  1993cites this paper
• Lipoprotein (a) promotes plasmin inhibition by alpha 2-antiplasmin.

  1992cites this paper
• Adsorption of plasminogen to glass and polyurethane surfaces

  1992cites this paper
• The tissue factor pathway of blood coagulation.

  1992cites this paper
• Binding Proteins of Protein Therapeutics

  1992cites this paper
• Beneficial Effects of Transforming Growth Factor-β and Tissue Plasminogen Activator in Splanchnic Artery Occlusion and Reperfusion in Cats

  1991cites this paper
• Enzymatic properties of t-PA/α2-macroglobulin complexes

  1991cites this paper
• Impaired fibrinolysis and risk of thromboembolism.

  1991cites this paper
• Quantification of functional and inactivated alpha 2-macroglobulin in sepsis.

  1991cites this paper
• Quantification of Functional and Inactivated α2-Macroglobulin in Sepsis

  1991cites this paper
• Complexing of tissue plasminogen activator with PAI-1, alpha 2-macroglobulin, and C1-inhibitor: studies in patients with defibrination and a fibrinolytic state after electroshock or complicated labor.

  1990cites this paper
• Plasminogen activation by t-PA on the surface of human melanoma cells in the presence of alpha 2-macroglobulin secretion.

  1990cites this paper
• The Conformation Changes of the Finger Domain of Tissue Type Plasminogen Activator during the Activator-lnhibitor Reaction

  1990cites this paper
• Plasminogen Activation at Low Temperatures in Plasma Samples Gontaining Therapeutic Concentrations of Tissue-Type Plasm i nogen Activator or Other Thrombolytic Agents

  1990cites this paper
• Fibrin polymerization and its regulatory role in hemostasis.

  1990cites this paper
• Interaction of a Plasmin A-Chain/t-PA B-Chain Hybrid Enzyme with Plasma Inhibitors In Vivo and In Vitro

  1990cites this paper
• The haemostatic balance in groups of thrombosis-prone patients. With particular reference to fibrinolysis in patients with myocardial infarction.

  1990cites this paper
• Tissue plasminogen activator: the biochemistry and pharmacology of variants produced by mutagenesis.

  1990cites this paper
• Glycosylation at Asn-184 inhibits the conversion of single-chain to two-chain tissue-type plasminogen activator by plasmin.

  1990cites this paper
• Fibrin Polymerization and its Role in Regulating Hemostasis

  1990cites this paper
• Thrombolytic properties of human tissue-type plasminogen activator, single-chain urokinase-type plasminogen activator, and synergistic combinations in venous thrombosis models in dogs and rabbits.

  1989cites this paper
• Catabolism of tissue-type plasminogen activator by the human hepatoma cell line Hep G2. Modulation by plasminogen activator inhibitor type 1.

  1989cites this paper
• Importance of Fibrin Specificity in Therapeutic Thrombolysis and the Rationale of Using Sequential and Synergistic Combinations of Tissue Plasminogen Activator and Pro-Urokinase

  1989cites this paper
• Interactions between tissue-type plasminogen activator and extracellular matrix-associated plasminogen activator inhibitor type 1 in the human hepatoma cell line HepG2.

  1989cites this paper
• On the Slow In Vitro Inhibition of Tissue Plasminogen Activator in Plasma and Platelet Lysates

  1989cites this paper
• Regulation of tissue plasminogen activator expression.

  1989cites this paper
• Bovine plasminogen activator inhibitor 1: specificity determinations and comparison of the active, latent, and guanidine-activated forms.

  1988cites this paper
• Metabolic Fate of Recombinant Human Tissue Plasminogen Activator (rt-PA) (1): Blood or Plasma Concentration, Distribution, Metabolism and Excretion in Rats after Single Intravenous Administration

  1988cites this paper
• Tissue plasminogen activator and inhibitors of fibrinolysis in malignant melanoma.

  1988cites this paper
• Tissue plasminogen activator.

  1988cites this paper
• Kinetic analysis of the interactions between plasminogen activator inhibitor 1 and both urokinase and tissue plasminogen activator.

  1988cites this paper
• Kinetic analysis of the interaction between plasminogen activator inhibitor-1 and tissue-type plasminogen activator.

  1988cites this paper
• Kinetics of inhibition of tissue-type and urokinase-type plasminogen activator by plasminogen-activator inhibitor type 1 and type 2.

  1988cites this paper
• Pathophysiology and clinical aspects of fibrinolysis and inhibition of coagulation. Experimental and clinical studies with special reference to women on oral contraceptives and selected groups of thrombosis prone patients.

  1988cites this paper
• Investigation by HPLC of the Catabolism of Recombinant Tissue Plasminogen Activator in the Rat

  1988cites this paper
• Circulatory metabolism of recombinant tissue-type plasminogen activator in monkeys and rabbits

  1988cites this paper
• Plasminogen activator inhibitors.

  1987cites this paper
• [New thrombolytic agents].

  1987cites this paper
• Increased concentration of the fast‐acting plasminogen activator inhibitor in plasma associated with familial venous thrombosis

  1987cites this paper
• 妊娠・分娩・産褥時の血中における種々の線溶促進・抑制因子の変動

  1987cites this paper
• Binding of tissue plasminogen activator to human umbilical vein endothelial cells.

  1987cites this paper
• Comparison of plasminogen activator inhibitor activity and antigen in plasma samples.

  1987cites this paper
• The Fibrinolytic System of Cultured Endothelial Cells

  1987cites this paper
• Functional role of proteolytic cleavage at arginine-275 of human tissue plasminogen activator as assessed by site-directed mutagenesis.

  1987cites this paper
• Plasminogen Activator Inhibitor-1 Is the Primary Inhibitor of Tissue-Type Plasminogen Activator in Pregnancy Plasma

  1987cites this paper
• A simplified estimation of tissue plasminogen activator (t-PA) inhibition in human plasma

  1987cites this paper
• Determinants of clearance of tissue-type plasminogen activator (t-PA) from the circulation

  1987cites this paper
• Initiation and regulation of fibrinolysis in human plasma at the plasminogen activator level.

  1987cites this paper
• Age dependence of tissue plasminogen activator concentrations in plasma, as studied by an improved enzyme-linked immunosorbent assay.

  1986cites this paper
• Absence of Synergism Between Tissue-Type Plasminogen Activator (t-PA), Single-Chain UrokinaseType Plasminogen Activator (scu-PA) and Urokinase on Clot Lysis in a Plasma Milieu In Vitro

  1986cites this paper
• Inhibition of one-chain and two-chain forms of human tissue-type plasminogen activator by the fast-acting inhibitor of plasminogen activator in vitro and in vivo.

  1986cites this paper
• Method for the determination of fast acting plasminogen activator inhibitor capacity (PAI-cap) in plasma, platelets and endothelial cells.

  1986cites this paper
• Advances in clinical fibrinolysis.

  1986cites this paper
• Determination ofTissuePlasminogen Activator andIts"Fast"Inhibitor in Plasma

  1986cites this paper
• The inactivation of one- and two-chain forms of tissue plasminogen activator by a series of peptidyl chloromethyl ketones.

  1986cites this paper
• Turnover of human tissue plasminogen activator (tPA) in rabbits.

  1986cites this paper
• The fibrinolytic system in man.

  1986cites this paper
• Plasminogen activator inhibitors in plasma and platelets from patients with recurrent venous thrombosis and pregnant women.

  1986cites this paper
• Determination of tissue plasminogen activator and its "fast" inhibitor in plasma.

  1986cites this paper
• Denaturant-induced stimulation of the beta-migrating plasminogen activator inhibitor in endothelial cells and serum.

  1986cites this paper
• Mechanisms of Enzymatic Fibrinolysis

  1986cites this paper
• Plasminogen activator inhibitor

  1986cites this paper
• Purification and characterization of a plasminogen activator inhibitor from the histiocytic lymphoma cell line U-937.

  1986cites this paper
• The fibrinolytic system of the vascular wall.

  1985cites this paper
• Immunoradiometric assay to measure the binding of a specific inhibitor to tissue-type plasminogen activator.

  1985cites this paper
• [Plasminogen activator of tissue type. Physiology, pathophysiology and clinical value].

  1985cites this paper
• A novel fast inhibitor to tissue plasminogen activator in plasma, which may be of great pathophysiological significance.

  1985cites this paper
• [Plasminogen activators: general aspects and recent developments].

  1985cites this paper
• Biological and Thrombolytic Properties of Natural and Recombinant Human Tissue-Type Plasminogen Activator (t-PA)

  1985cites this paper
• Plasminogen activators, tissue degradation, and cancer.

  1985cites this paper
• Tissue plasminogen activator inhibitor in the epidermis

  1985cites this paper
• Human Leucocyte Urokinase Inhibitor - Purification, Characterization and Comparative Studies Against Different Plasminogen Activators

  1985cites this paper
• Tissue plasminogen activator and urokinase mediate the binding of Glu-plasminogen to plasma fibrin I. Evidence for new binding sites in plasmin-degraded fibrin I.

  1985cites this paper
• The primary plasminogen-activator inhibitors in endothelial cells, platelets, serum, and plasma are immunologically related.

  1985cites this paper
• Effect of various agents on ovarian plasminogen activator activity during ovulation in pregnant mare's serum gonadotropin-primed immature rats.

  1985cites this paper
• Problems on t-PA Specific Inhibitor Determination in Human Plasma

  1985cites this paper